CYP2E1 and steatosis: Many issues need to be addressed before determining the roles of the CYP4A11-mediated 20-HETE and CYP2E1-related 19-HETE in steatosis, steatohepatitis, cirrhosis, and HCC, and possible therapeutic targets in the treatment of CLD.